News

EyeBio is developing a pipeline of clinical and preclinical candidates for the prevention and treatment of vision loss associated with retinal vascular leakage.

Researchers from the UKB Eye Clinic, in cooperation with the University of Bonn and in close collaboration with basic and clinical scientists, have examined patients with early forms of AMD. The researchers focused on the so-called iRORA lesions, which are very early anatomical signs of retinal damage.

The approach to treating amblyopia in young children couples proprietary therapeutic software with virtual reality (VR) headsets and popular children's TV shows

Investigators conducted a case-control study to investigate the corneal topography parameters and biomechanics in patients with alopecia areata

Researchers, led by Shigemi Matsuyama, PhD, will conduct research seeking a potential breakthrough drug that can be taken orally—one that may address many RP disease manifestations, regardless of the underlying genetic mutation.

The organization has secured £72.75 million for its new eye health center.

AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of North Carolina at Chapel Hill.

Ophthalmologists were able to remove the stinger after identifying its location during a slit lamp examination.

Companies continue to share news about the data that will be presented at the 2024 ASRS meeting in Stockholm, Sweden.

The organisation has secured £72.75 million for its new eye health centre

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

A novel formulation may prevent blood vessel growth and vascular leakage in the retina.

The companies are teaming up to reduce care gaps and improve eye and vision health by bringing diabetic retinopathy and other eye disease screening services to patients in their own homes and workplaces.

A novel formulation may prevent blood vessel growth and vascular leakage in the retina

A team of researchers at the Ohio State University found that in mice an enzyme related to cell growth and division is a culprit in the blood vessel invasion in the back of the eye that causes blurred central vision in wet AMD.

Ophthalmologist receives the Roger Steinert, MD, Legacy Award during the Octane Ophthalmology Tech Forum in Irvine, California.

According to the company, FYSX is the first non-pharmacological, non-surgical treatment designed to lower IOP for glaucoma patients.

Prescriptions with semaglutide (Wegovy, Ozempic, Novo Nordisk) are FDA approved to treat obesity and type 2 diabetes, respectively.

Chris Brittain, vice president, Global Head of Ophthalmology Product Development at Genentech, sat with Ophthalmology Times to discuss the company's plans with Susvimo following the FDA approval for relaunch.

GLP-1 receptor agonists, such as Wegovy, Ozempic and Novo Nordisk, are becoming more prolific

The company announced it has received FDA approval to relaunch Susvimo for intravitreal use via an ocular implant for treating people with wet AMD.

The company has secured $170 million (approximately €157 million) in Series B funding

NVK002 atropine 0.01% (Vyluma Inc.) “meaningfully slowed” myopia progression in myopic pediatric patients over a 36-month period.

Most respondents were unsure of how to seek treatment and see dry eye as something that must be learned to live with.

The company states this will enable movement toward US approval

The funding will go toward the continued clinical development of the company’s lead asset, AGTC-501 (laruparetigene zovaparvovec)

Technology offers increased usability, safety, and accuracy in MIGS procedures.

Extended daylight hours and plentiful outdoor space make Stockholm a memorable destination for meeting attendees